Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Kaveri Pohlman is an analyst at BTIG. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 03/29/2025
| Buy Now | Get Alert | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 08/01/2024 | MGNX | Buy Now | Macrogenics | $1.25 | — | Kaveri Pohlman25% | — | Downgrade | Buy → Neutral | Get Alert |
| 06/27/2024 | GMAB | Buy Now | Genmab | $19.94 | 135.71% | Kaveri Pohlman25% | $46 → $47 | Maintains | Buy | Get Alert |
| 05/24/2024 | MGNX | Buy Now | Macrogenics | $1.25 | 620% | Kaveri Pohlman25% | $24 → $9 | Maintains | Buy | Get Alert |
| 04/17/2024 | CGEM | Buy Now | Cullinan Oncology | $8.02 | 274.06% | Kaveri Pohlman25% | $20 → $30 | Maintains | Buy | Get Alert |
| 04/16/2024 | XNCR | Buy Now | Xencor | $11.23 | 238.38% | Kaveri Pohlman25% | $56 → $38 | Maintains | Buy | Get Alert |
| 03/26/2024 | NUVB | Buy Now | Nuvation Bio | $1.82 | 174.73% | Kaveri Pohlman25% | → $5 | Upgrade | Neutral → Buy | Get Alert |
| 03/21/2024 | JANX | Buy Now | Janux Therapeutics | $29.10 | 113.06% | Kaveri Pohlman25% | → $62 | Initiates | → Buy | Get Alert |
| 03/04/2024 | MGNX | Buy Now | Macrogenics | $1.25 | 1820% | Kaveri Pohlman25% | $12 → $24 | Maintains | Buy | Get Alert |
| 02/09/2024 | PYXS | Buy Now | Pyxis Oncology | $1.07 | 647.66% | Kaveri Pohlman25% | → $8 | Initiates | → Buy | Get Alert |
| 12/19/2023 | EXEL | Buy Now | Exelixis | $36.65 | -26.33% | Kaveri Pohlman25% | → $27 | Initiates | → Buy | Get Alert |
| 10/13/2023 | GMAB | Buy Now | Genmab | $19.94 | 130.69% | Kaveri Pohlman25% | $44 → $46 | Maintains | Buy | Get Alert |
| 09/12/2023 | AMAM | Buy Now | Ambrx Biopharma | — | — | Kaveri Pohlman25% | → $26 | Initiates | → Buy | Get Alert |
| 08/24/2023 | GMAB | Buy Now | Genmab | $19.94 | 120.66% | Kaveri Pohlman25% | → $44 | Initiates | → Buy | Get Alert |
| 08/23/2023 | RCUS | Buy Now | Arcus Biosciences | $8.17 | 756.79% | Kaveri Pohlman25% | → $70 | Reiterates | Buy → Buy | Get Alert |
| 03/21/2023 | MGNX | Buy Now | Macrogenics | $1.25 | 860% | Kaveri Pohlman25% | $6 → $12 | Maintains | Buy | Get Alert |
| 11/21/2022 | CGEM | Buy Now | Cullinan Oncology | $8.02 | 149.38% | Kaveri Pohlman25% | → $20 | Initiates | → Buy | Get Alert |
| 11/14/2022 | ONCS | Buy Now | OncoSec Medical | — | — | Kaveri Pohlman25% | — | Downgrade | Buy → Neutral | Get Alert |
| 08/31/2022 | STTK | Buy Now | Shattuck Labs | $1.14 | 953.46% | Kaveri Pohlman25% | → $12 | Initiates | → Buy | Get Alert |
| 08/02/2022 | NUVB | Buy Now | Nuvation Bio | $1.82 | — | Kaveri Pohlman25% | — | Downgrade | Buy → Neutral | Get Alert |
| 07/07/2022 | CTMX | Buy Now | CytomX Therapeutics | $0.60 | 1232.67% | Kaveri Pohlman25% | $16 → $8 | Maintains | Buy | Get Alert |
| 06/01/2022 | NEXI | Buy Now | NexImmune | — | — | Kaveri Pohlman25% | → $125 | Initiates | → Buy | Get Alert |
| 04/20/2022 | CMPI | Buy Now | Checkmate Pharmaceuticals | — | — | Kaveri Pohlman25% | — | Downgrade | Buy → Neutral | Get Alert |
| 03/30/2022 | CMPI | Buy Now | Checkmate Pharmaceuticals | — | — | Kaveri Pohlman25% | $29 → $9 | Maintains | Buy | Get Alert |
| 03/16/2022 | ONCS | Buy Now | OncoSec Medical | — | — | Kaveri Pohlman25% | $220 → $110 | Maintains | Buy | Get Alert |
| 02/24/2022 | ONCT | Buy Now | Oncternal Therapeutics | — | — | Kaveri Pohlman25% | → $100 | Initiates | → Buy | Get Alert |
| 02/09/2022 | SONN | Buy Now | Sonnet BioTherapeutics | $1.33 | 50.38% | Kaveri Pohlman25% | $12320 → $4928 | Maintains | Buy | Get Alert |
| 11/15/2021 | CTMX | Buy Now | CytomX Therapeutics | $0.60 | 2565.33% | Kaveri Pohlman25% | → $16 | Initiates | → Buy | Get Alert |
| 09/15/2021 | SONN | Buy Now | Sonnet BioTherapeutics | $1.33 | 275.94% | Kaveri Pohlman25% | → $12320 | Initiates | → Buy | Get Alert |
